The Double-Edged Sword: How Antimicrobial Peptides Drive and Dampen Autoimmune Diseases | Research

The takeaway

Human antimicrobial peptides play dual roles in autoimmune diseases — both promoting and suppressing inflammation in conditions from diabetes to lupus to psoriasis.

6 diseases
Autoimmune conditions where AMPs play documented dual pro- and anti-inflammatory roles

What the researchers found

Human AMPs have dual roles in autoimmune diseases — they can both promote inflammation (e.g., LL-37 in psoriasis) and suppress it (e.g., defensins in some contexts), depending on the disease and immune environment.

Why it matters

Understanding the dual nature of AMPs in autoimmunity is essential for developing therapies that can selectively modulate their pro- or anti-inflammatory effects.

The numbers in context

6 autoimmune diseases reviewed; dual pro/anti-inflammatory roles; complement modulation identified

How the study worked

Narrative review of published literature on AMP involvement in six major autoimmune disorders.

Who was studied

Review article (no study population)

What this study cannot tell us

Review article. The complex, context-dependent roles of AMPs make simple therapeutic targeting challenging.

How to read the evidence

Comprehensive review synthesizing evidence across multiple autoimmune diseases. Strong overview but no new data.

When this study was published

Published in 2020. AMP roles in autoimmunity continue to be a growing research area.

The bigger picture

AMPs sit at the intersection of antimicrobial defense and immune regulation, making them key players in autoimmune disease that could be targeted therapeutically.

Questions still open

Can AMP-targeted therapies selectively suppress autoimmune inflammation without compromising antimicrobial defense?
Do AMP levels serve as biomarkers for autoimmune disease activity?
Which AMP is the most promising therapeutic target across autoimmune diseases?

Common questions

How can antimicrobial peptides cause autoimmune disease?

AMPs can activate immune cells, enhance inflammatory signaling, and in some cases become targets of autoimmune attack themselves (as with LL-37 in psoriasis). Their ability to modulate both innate and adaptive immunity means they can tip the immune balance toward harmful autoimmune responses.

Can blocking AMPs treat autoimmune diseases?

Potentially, but it's complicated. AMPs play dual roles — they can both promote and suppress inflammation depending on the disease context. Any therapy would need to selectively target the harmful AMP effects while preserving their protective antimicrobial and anti-inflammatory functions.

Read the original research

Human antimicrobial peptides in autoimmunity.

Autoimmunity, 53(3), 137-147

View on PubMed ↗Publisher’s paper ↗

Citation

Umnyakova, Ekaterina S; Zharkova, Maria S; Berlov, Mikhail N; Shamova, Olga V; Kokryakov, Vladimir N. (2020). Human antimicrobial peptides in autoimmunity.. Autoimmunity, 53(3), 137-147. https://doi.org/10.1080/08916934.2020.1711517